Prime Medicine (PRME) Liabilities and Shareholders Equity (2021 - 2026)

Prime Medicine's Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $294.7 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 10.19% year-over-year to $294.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 6.84% YoY) and the FY2025 annual result came in at $342.7 million, up 15.2% from the prior year.
• Liabilities and Shareholders Equity was $294.7 million for Q1 2026 at Prime Medicine, down from $342.7 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $385.0 million in Q3 2025 and bottomed at $193.9 million in Q4 2023.
• A 5-year average of $295.8 million and a median of $297.5 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity slumped 46.2% — and 2024, when it jumped 53.47%.
• Prime Medicine's Liabilities and Shareholders Equity stood at $360.3 million in 2022, then tumbled by 46.2% to $193.9 million in 2023, then jumped by 53.47% to $297.5 million in 2024, then climbed by 15.2% to $342.7 million in 2025, then declined by 14.01% to $294.7 million in 2026.
• Business Quant data shows PRME's Liabilities and Shareholders Equity at $294.7 million in Q1 2026, $342.7 million in Q4 2025, and $385.0 million in Q3 2025.